Favipiravir, will it be the Answer for the Specific Management of COVID-19?: A Review

Authors

  • Jayant Patharkar1 , Maulin Mehta2 , Janhavi Patharkar3

DOI:

https://doi.org/10.37506/mlu.v21i1.2340

Keywords:

COVID-19 management, clinical trials review,Favipiravir, repurpose drug

Abstract

Background: The COVID-19 has created havoc all over the world as no specific treatment available till
date. Total COVID-19 cases had crossed 11,125,245 including 528,204 deaths as per the WHO data till 5
July 2020. Unfortunately, India secured third place in total tally of COVID-19 cases with 6,77,719 total
cases including 19693 deaths as of 5th July 2020. The antiviral drug, Favipiravir, previously known as T-705
approved in Japan for treatment of Influenza. It is selective & potent inhibitor of viral RNA polymerase. It
is promising drug for treatment of wide range of RNA viruses including SARSCoV-2.
Method: The systematic review of Articles was done with the help of search engines like Embase, Medline,
PubMed & Google Scholar, clinicaltrials.gov. The Peer reviewed articles published through 6th of July 2020
were included in the study. This review was done to establish clinical evidence for use of Favipiravir in
COVID-19.
Conclusion: It was found that due to lack of conclusive evidence, Favipiravir cannot be included in main
armamentarium for COVID-19.

Author Biography

Jayant Patharkar1 , Maulin Mehta2 , Janhavi Patharkar3

1Assistant Professor, 2Associate Professor,Department of Pharmacology, Smt. B.K. Shah Medical Institute &
Research Centre, Sumandeep Vidyapeeth Deemed to be University, At. & Post. PIPARIA, Tal. Waghodia, Dist.
Vadodara-391760, Gujarat State, 3
Assistant Professor, Department of Kayachikitsa, Parul Institute of Ayurved, At.
& Post. Limda, Tal. Waghodia, Dist. Vadodara-391760, Gujarat state.

Published

2021-01-09

How to Cite

Jayant Patharkar1 , Maulin Mehta2 , Janhavi Patharkar3. (2021). Favipiravir, will it be the Answer for the Specific Management of COVID-19?: A Review. Medico Legal Update, 21(1), 389-392. https://doi.org/10.37506/mlu.v21i1.2340